Optimizing treatment in recurrent epithelial ovarian cancer

G Corrado, V Salutari, E Palluzzi… - Expert review of …, 2017 - Taylor & Francis
Introduction: Optimal management of recurrent ovarian cancer (ROC) remains an area of
uncertainty. An estimated 85% of patients with epithelial ovarian cancer who achieve a full …

[HTML][HTML] Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status

…, G Scandurra, C Zamagni, P Zola, V Salutari - Journal of Ovarian …, 2019 - Springer
Epithelial ovarian cancer is the most lethal gynecologic malignancy. In most women, it is
diagnosed at an advanced stage, which largely explains the poor prognosis of this …

[HTML][HTML] PARP inhibitors resistance: mechanisms and perspectives

E Giudice, M Gentile, V Salutari, C Ricci, L Musacchio… - Cancers, 2022 - mdpi.com
Simple Summary This review aims to analyze the emerging issue regarding PARP inhibitor's
resistance in tumors and their consequence on disease prognosis and treatment. Besides …

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

…, V Murgia, C Sacco, S Cinieri, V Salutari… - The lancet …, 2014 - thelancet.com
Background Carboplatin plus paclitaxel administered every 3 weeks is standard first-line
chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule …

[HTML][HTML] Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 …

…, S Greggi, C Pisano, D Lorusso, V Salutari… - Journal of clinical …, 2011 - nlp.case.edu
Purpose Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with
advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an …

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a …

…, N Colombo, C Sessa, A Bamias, V Salutari… - The Lancet …, 2021 - thelancet.com
Background Bevacizumab is approved in combination with chemotherapy for the treatment
of ovarian cancer, either in first-line therapy or for patients with recurrent disease not …

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open …

…, F Raspagliesi, G Maltese, V Salutari… - The Lancet …, 2015 - thelancet.com
Background Inhibition of angiogenesis is a valuable treatment strategy for ovarian cancer.
Pazopanib is an anti-angiogenic drug active in ovarian cancer. We assessed the effect of …

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer …

…, J Korach, T Huzarski, L Vidal, V Salutari… - The Lancet …, 2018 - thelancet.com
Background In the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib
tablets significantly prolonged progression-free survival (primary endpoint) compared with …

Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome

SC Cecere, G Giannone, V Salutari, L Arenare… - Gynecologic …, 2020 - Elsevier
Objectives Olaparib is approved as maintenance therapy in patients with BRCA mutated
platinum sensitive (PS) recurrent ovarian cancer (OC) after response to last platinum based …

LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) …

…, B Ataseven, MJ Rubio, V Salutari… - Annals of …, 2020 - annalsofoncology.org
Background Cyclins are proteins that activate cyclin-dependent kinases (CDKs) and are
required for normal cell cycle transitions. Palbociclib is an oral selective inhibitor of the …